glp-1 and gip receptors receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Frontiers | Mechanisms of action

Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats

According to King Law: The lawsuits primarily allege that manufacturers like Novo Nordisk (maker of Wegovy) failed to adequately warn patients and healthcare providers about the risks associated with these drugs, such as severe gastrointestinal complications like gastroparesis (stomach paralysis), ileus (intestinal obstruction), and recently, vision loss due to non-arteritic anterior ischemic optic neuropathy (NAION). Prediction 2: More Emergency Room Visits Due to Adverse Effects In April 2025, Annals of Medicine reported that nearly 25,000 emergency room visits had occurred due to semaglutide adverse events in the years 2022 and 2023

For current customers, those decisions will be made with the renewal of their health plan, the statement said

In isolation, glucagon receptor activation would not be expected to serve as an ideal diabetes or obesity therapy